Difference between revisions of "Rilzabrutinib (PRN-1008)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - " (NCT[0-9]{8})" to " https://clinicaltrials.gov/ct2/show/$1") |
Warner-admin (talk | contribs) m (Text replacement - " (https:\/\/clinicaltrials.gov\/ct2\/show\/NCT[0-9]{8})" to " [$1 Clinical Trials Registry]") |
||
| Line 6: | Line 6: | ||
==Preliminary data== | ==Preliminary data== | ||
===[[Immune thrombocytopenia]]=== | ===[[Immune thrombocytopenia]]=== | ||
| − | #'''PRN1008-010:''' Kuter DJ, Efraim M, Mayer J, Trněný M, McDonald V, Bird R, Regenbogen T, Garg M, Kaplan Z, Tzvetkov N, Choi PY, Jansen AJG, Kostal M, Baker R, Gumulec J, Lee EJ, Cunningham I, Goncalves I, Warner M, Boccia R, Gernsheimer T, Ghanima W, Bandman O, Burns R, Neale A, Thomas D, Arora P, Zheng B, Cooper N. Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia. N Engl J Med. 2022 Apr 14;386(15):1421-1431. [https://doi.org/10.1056/nejmoa2110297 link to original article] [https://pubmed.ncbi.nlm.nih.gov/35417637/ PubMed] https://clinicaltrials.gov/ct2/show/NCT03395210 | + | #'''PRN1008-010:''' Kuter DJ, Efraim M, Mayer J, Trněný M, McDonald V, Bird R, Regenbogen T, Garg M, Kaplan Z, Tzvetkov N, Choi PY, Jansen AJG, Kostal M, Baker R, Gumulec J, Lee EJ, Cunningham I, Goncalves I, Warner M, Boccia R, Gernsheimer T, Ghanima W, Bandman O, Burns R, Neale A, Thomas D, Arora P, Zheng B, Cooper N. Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia. N Engl J Med. 2022 Apr 14;386(15):1421-1431. [https://doi.org/10.1056/nejmoa2110297 link to original article] [https://pubmed.ncbi.nlm.nih.gov/35417637/ PubMed] [https://clinicaltrials.gov/ct2/show/NCT03395210 Clinical Trials Registry] |
==Also known as== | ==Also known as== | ||
Revision as of 20:35, 17 June 2023
General information
Class/mechanism: BTK inhibitor
Route: PO
Extravasation: n/a
Preliminary data
Immune thrombocytopenia
- PRN1008-010: Kuter DJ, Efraim M, Mayer J, Trněný M, McDonald V, Bird R, Regenbogen T, Garg M, Kaplan Z, Tzvetkov N, Choi PY, Jansen AJG, Kostal M, Baker R, Gumulec J, Lee EJ, Cunningham I, Goncalves I, Warner M, Boccia R, Gernsheimer T, Ghanima W, Bandman O, Burns R, Neale A, Thomas D, Arora P, Zheng B, Cooper N. Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia. N Engl J Med. 2022 Apr 14;386(15):1421-1431. link to original article PubMed Clinical Trials Registry
Also known as
- Code name: PRN-1008